Related Experiment Video
Updated: Jun 21, 2026

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
Published on: January 5, 2016
A new subtype of frontotemporal lobar degeneration with FUS pathology
Manuela Neumann1, Rosa Rademakers, Sigrun Roeber
1Institute of Neuropathology, University Hospital of Zürich, Zürich, Switzerland.
Abstract:
Frontotemporal dementia (FTD) is a clinical syndrome with a heterogeneous molecular basis. The neuropathology associated with most FTD is characterized by abnormal cellular aggregates of either transactive response DNA-binding protein with Mr 43 kDa (TDP-43) or tau protein. However, we recently described a subgroup of FTD patients, representing around 10%, with an unusual clinical phenotype and pathology characterized by frontotemporal lobar degeneration with neuronal inclusions composed of an unidentified ubiquitinated protein (atypical FTLD-U; aFTLD-U). All cases were sporadic and had early-onset FTD with severe progressive behavioural and personality changes in the absence of aphasia or significant motor features. Mutations in the fused in sarcoma (FUS) gene have recently been identified as a cause of familial amyotrophic lateral sclerosis, with these cases reported to have abnormal cellular accumulations of FUS protein. Because of the recognized clinical, genetic and pathological overlap between FTD and amyotrophic lateral sclerosis, we investigated whether FUS might also be the pathological protein in aFTLD-U. In all our aFTLD-U cases (n = 15), FUS immunohistochemistry labelled all the neuronal inclusions and also demonstrated previously unrecognized glial pathology. Immunoblot analysis of protein extracted from post-mortem aFTLD-U brain tissue demonstrated increased levels of insoluble FUS. No mutations in the FUS gene were identified in any of our patients. These findings suggest that FUS is the pathological protein in a significant subgroup of sporadic FTD and reinforce the concept that FTD and amyotrophic lateral sclerosis are closely related conditions.
Insights
Frontotemporal dementia (FTD) pathology can involve abnormal tau or TDP-43 proteins. This study identifies fused in sarcoma (FUS) protein aggregates in a unique FTD subgroup, suggesting FUS is a key factor in some sporadic FTD cases.
Area of Science:
- Neuroscience
- Neuropathology
- Genetics
Background:
- Frontotemporal dementia (FTD) presents heterogeneously, often involving tau or TDP-43 protein aggregates.
- A subset of FTD patients exhibits atypical frontotemporal lobar degeneration with neuronal inclusions (aFTLD-U), with an unknown pathological basis.
- FTD and amyotrophic lateral sclerosis (ALS) share clinical, genetic, and pathological overlaps.
Purpose of the Study:
- To investigate if fused in sarcoma (FUS) protein is the pathological agent in atypical FTLD-U (aFTLD-U).
- To explore the role of FUS in sporadic FTD cases with unusual presentations.
Main Methods:
- Immunohistochemistry using FUS antibodies on post-mortem brain tissue from aFTLD-U patients.
- Immunoblot analysis to assess insoluble FUS protein levels in affected brain tissue.
- Genetic analysis of the FUS gene in patient cohorts.
Main Results:
- FUS immunohistochemistry confirmed FUS protein aggregates in neuronal inclusions and glial pathology in all aFTLD-U cases (n=15).
- Increased insoluble FUS levels were detected in post-mortem aFTLD-U brain tissue.
- No FUS gene mutations were found in the studied sporadic FTD patients.
Conclusions:
- Fused in sarcoma (FUS) protein is the pathological hallmark in a significant subgroup of sporadic atypical FTD.
- These findings support the close relationship between FTD and ALS.
- FUS pathology should be considered in the differential diagnosis of early-onset FTD with behavioral changes.
Related Concept Videos
Association Areas of the Cortex
Prefrontal Association Area: This area is located in the frontal lobe and is involved in planning, decision-making, and moderating social behavior. It connects with primary motor areas,...
Alzheimer Disease ll: Pathophysiology
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Dementia l: Introduction
Huntington Disease l: Introduction

